Literature DB >> 33908009

Evaluating N-Glycosylation of a Therapeutic Monoclonal Antibody Using UHPLC-FLR-MS with RapiFluor-MS Labeling.

Rosie Upton1, James Duffy2, Sam Clawson2, David Firth2.   

Abstract

Released N-glycan analysis using the fluorescent label 2-AB (2-aminobenzamide) has been the "gold standard" method for released glycan analysis for several years. The more recent RapiFluor-MS™ labeling technique, however, offers enhanced mass spectrometric detection of released N-glycans, improving the sensitivity and detection limits of the method. The optimized multidimensional detection offers increased confidence in glycan identification which can be further supported by an exoglycosidase digestion array (optional). Here we describe the PNGase F release of N-glycans from a typical IgG1 monoclonal antibody (mAb) with subsequent labeling with RapiFluor-MS™ for detection by HILIC-FLR-MS. The method output quantifies the relative proportion of each glycan species including core afucosylation, sialylation, and high-mannose content, and has a limit of detection (LOD) of 0.01% relative abundance.

Entities:  

Keywords:  Antibody; Glycan profiling; LC-MS; RapiFluor-MS ™ labeling

Year:  2021        PMID: 33908009     DOI: 10.1007/978-1-0716-1241-5_14

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

Review 1.  Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs.

Authors:  Peiqing Zhang; Susanto Woen; Tianhua Wang; Brian Liau; Sophie Zhao; Chen Chen; Yuansheng Yang; Zhiwei Song; Mark R Wormald; Chuanfei Yu; Pauline M Rudd
Journal:  Drug Discov Today       Date:  2016-01-25       Impact factor: 7.851

2.  High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.

Authors:  Andrew M Goetze; Y Diana Liu; Zhongqi Zhang; Bhavana Shah; Edward Lee; Pavel V Bondarenko; Gregory C Flynn
Journal:  Glycobiology       Date:  2011-03-18       Impact factor: 4.313

Review 3.  Glycosylation of recombinant antibody therapeutics.

Authors:  Royston Jefferis
Journal:  Biotechnol Prog       Date:  2005 Jan-Feb

Review 4.  Production of therapeutic antibodies with controlled fucosylation.

Authors:  Naoko Yamane-Ohnuki; Mitsuo Satoh
Journal:  MAbs       Date:  2009-05-28       Impact factor: 5.857

Review 5.  Effective use of mass spectrometry for glycan and glycopeptide structural analysis.

Authors:  Nancy Leymarie; Joseph Zaia
Journal:  Anal Chem       Date:  2012-03-06       Impact factor: 6.986

6.  Rapid Preparation of Released N-Glycans for HILIC Analysis Using a Labeling Reagent that Facilitates Sensitive Fluorescence and ESI-MS Detection.

Authors:  Matthew A Lauber; Ying-Qing Yu; Darryl W Brousmiche; Zhengmao Hua; Stephan M Koza; Paula Magnelli; Ellen Guthrie; Christopher H Taron; Kenneth J Fountain
Journal:  Anal Chem       Date:  2015-05-08       Impact factor: 6.986

7.  Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Authors:  Robert L Shields; Jadine Lai; Rodney Keck; Lori Y O'Connell; Kyu Hong; Y Gloria Meng; Stefanie H A Weikert; Leonard G Presta
Journal:  J Biol Chem       Date:  2002-05-01       Impact factor: 5.157

8.  Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.

Authors:  Akira Okazaki; Emi Shoji-Hosaka; Kazuyasu Nakamura; Masako Wakitani; Kazuhisa Uchida; Shingo Kakita; Kouhei Tsumoto; Izumi Kumagai; Kenya Shitara
Journal:  J Mol Biol       Date:  2004-03-05       Impact factor: 5.469

Review 9.  Fc glycans of therapeutic antibodies as critical quality attributes.

Authors:  Dietmar Reusch; Max L Tejada
Journal:  Glycobiology       Date:  2015-08-11       Impact factor: 4.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.